Teladoc (TDOC) PT Raised to $6 at Jefferies

Jefferies analyst Glen Santangelo raised the price target on Teladoc (NYSE: TDOC) to $6.00 (from $5.20) while maintaining a Hold rating.

The analyst comments "TDOC had a good Q1, with Integrated Care delivering positive rev growth and BetterHelp progressing ahead of plan on its move to expand its insured patients revenue base. This good performance was adequately rewarded with a +6% post-release move in the stock. We are gaining optimism in the story, but choose to keep our Hold as we continue to watch the BetterHelp strategic transition. Raising PT to $6."

You May Also Be Interested In

• Jefferies Upgrades Tango Therapeutics Inc. (TNGX) to Buy
• Oppenheimer Starts Eupraxia Pharmaceuticals (EPRX) at Outperform
• JPMorgan's Dimon likely to continue as CEO for another three years - Reuters